Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued on Wednesday. The firm set a “sell” rating on the stock.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.21 on Wednesday. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $7.98. The stock’s fifty day moving average is $0.62 and its two-hundred day moving average is $2.39. The company has a market capitalization of $5.63 million, a P/E ratio of -0.07 and a beta of 1.31. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the previous year, the business earned ($1.35) earnings per share. Equities analysts expect that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently modified their holdings of SYRS. Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the period. Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth about $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.